Thank you to our clinician partners for over 10 years of life-changing TAVR procedures

This year marks the milestone of 10 years of the Edwards SAPIEN valve in the United States. We are honored for your continued partnership and to share this achievement with you.

To celebrate, Larry L. Wood, Edwards Corporate Vice President, and Marty B. Leon, MD., a principal investigator of the PARTNER 3 trial, have a special message for all of our physicians who have helped make Edwards TAVR what it is today.

Watch a special message from Larry L. Wood and Marty B. Leon, MD

Watch now

The valve designed to meet your Higher Standard.

Scroll / swipe side to side to review timeline

*The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehospitalization (valve-related or procedure-related and including heart failure) and multiple pre-specified secondary endpoints.

References:   1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.